StreetInsider.com News Articles

Form 10-Q MILESTONE SCIENTIFIC For: Jun 30

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921104.html

Form 10-Q MILESTONE SCIENTIFIC For: Jun 30

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921104.html

Milestone Scientific Schedules Second Quarter 2026 Financial Results Conference Call

Thu, 06 Aug 2026 08:47:00 -0400

ROSELAND, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, August 14, 2026, to discuss the company’s financial results for the second quarter ended June 30, 2026, as well as the company’s corporate progress and other developments.

The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering

Milestone Scientific Schedules Second Quarter 2026 Financial Results Conference Call

Thu, 06 Aug 2026 08:47:00 -0400

The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering

Milestone Scientific Schedules Second Quarter 2026 Financial Results Conference Call

Thu, 06 Aug 2026 08:47:00 -0400

The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering

Milestone Scientific Schedules Second Quarter 2026 Financial Results Conference Call

Thu, 06 Aug 2026 08:47:00 -0400

The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering

Form 8-K MILESTONE SCIENTIFIC For: Jul 27

Fri, 31 Jul 2026 11:50:00 -0400

si-local-file:///var/storage/secattach/20260731/26848985.html

Form 8-K MILESTONE SCIENTIFIC For: Jul 27

Fri, 31 Jul 2026 11:50:00 -0400

si-local-file:///var/storage/secattach/20260731/26848985.html

Form 8-K MILESTONE SCIENTIFIC For: Jul 24

Wed, 29 Jul 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260729/26836641.html

Form 8-K MILESTONE SCIENTIFIC For: Jul 24

Wed, 29 Jul 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260729/26836641.html

Milestone Scientific (MLSS) Reiterated at Speculative Buy by Benchmark on Q2 Revenue

Thu, 02 Jul 2026 08:10:20 -0400

Benchmark analyst Bruce Jackson reiterated a Speculative Buy rating and $1.00 price target on Milestone Scientific (NYSE: MLSS).

The analyst commented, "Milestone Scientific pre-announced 2Q 2026 revenue of approximately $2.8 million, slightly ahead of our estimate of $2.6 million and consensus of $2.5 million. The Dental segment is expected to contribute approximately $2.4 million in revenue for the quarter and drove the overall business, while the Medical segment is expected to accelerate during 2H 2026. The company plans to showcase their technology at the upcoming American Society of Pain & Neuroscience (ASPN) Conference in Miami Beach from July 16–18. No change

Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY

Wed, 01 Jul 2026 08:30:00 -0400

Medical Segment Momentum Accelerates, Posting 300% Growth Versus Q2 2025

Company to Showcase Technology at American Society of Pain & Neuroscience Conference in Miami Beach, July 16–18, Alongside Board Member and ASPN Co-Founder and Vice Chairman, Dr. Dawood Sayed

ROSELAND, N.J., July 01, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced preliminary, unaudited revenue for the second quarter ending June 30, 2026.

The Company expects total revenue of approximately $2.8 million for the second

Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY

Wed, 01 Jul 2026 08:30:00 -0400

Medical Segment Momentum Accelerates, Posting 300% Growth Versus Q2 2025

Company to Showcase Technology at American Society of Pain & Neuroscience Conference in Miami Beach, July 16–18, Alongside Board Member and ASPN Co-Founder and Vice Chairman, Dr. Dawood Sayed

The Company expects total revenue of approximately $2.8 million for the second

Milestone Scientific adds two directors, shifts chair to executive role

Thu, 25 Jun 2026 09:04:25 -0400

Milestone Scientific Inc. (NYSE: MLSS) announced changes to its board of directors, including the appointment of two independent directors and a leadership transition at the board level.

Benedetta I. Casamento has moved from Chair of the Board to Executive Chair, a role in which she will work with the management team on strategic guidance and execution of company objectives.

Greg Shilling and Kelly Ann Ulto have been appointed as independent board members. Shilling has more than 30 years of experience in healthcare technology, software, artificial intelligence and cybersecurity, and currently serves as Partner and General Manager of 121G and 10Bridge. He previously

Milestone Scientific adds two directors, shifts chair to executive role

Thu, 25 Jun 2026 09:04:25 -0400

Milestone Scientific Inc. (NYSE: MLSS) announced changes to its board of directors, including the appointment of two independent directors and a leadership transition at the board level.

Benedetta I. Casamento has moved from Chair of the Board to Executive Chair, a role in which she will work with the management team on strategic guidance and execution of company objectives.

Milestone Scientific Strengthens Board to Support Next Phase of Growth

Thu, 25 Jun 2026 09:00:00 -0400

Appoints Two Independent Directors with Deep Healthcare, Technology and Financial Expertise Chair of the Board Transitions to Executive Chair to Drive Strategic Execution

ROSELAND, N.J., June 25, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced a series of strategic governance initiatives designed to support the Company’s continued evolution and long-term growth. These actions include strengthening the Board of Directors with two highly experienced independent directors, transitioning Board leadership to support closer strategic execution and aligning with the Company's founder through a

Milestone Scientific Strengthens Board to Support Next Phase of Growth

Thu, 25 Jun 2026 09:00:00 -0400

Appoints Two Independent Directors with Deep Healthcare, Technology and Financial Expertise Chair of the Board Transitions to Executive Chair to Drive Strategic Execution

Form 8-K MILESTONE SCIENTIFIC For: Apr 30

Thu, 25 Jun 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260625/26689105.html

Form 8-K MILESTONE SCIENTIFIC For: Apr 30

Thu, 25 Jun 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260625/26689105.html

Form DEF 14A MILESTONE SCIENTIFIC For: Jun 22

Mon, 22 Jun 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20260622/26672367.html

Form DEF 14A MILESTONE SCIENTIFIC For: Jun 22

Mon, 22 Jun 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20260622/26672367.html

Form PRER14A MILESTONE SCIENTIFIC

Wed, 10 Jun 2026 13:58:00 -0400

si-local-file:///var/storage/secattach/20260610/26629212.html

Form PRER14A MILESTONE SCIENTIFIC

Wed, 10 Jun 2026 13:58:00 -0400

si-local-file:///var/storage/secattach/20260610/26629212.html

Form EFFECT MILESTONE SCIENTIFIC

Wed, 10 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260610/26626131.html

Form EFFECT MILESTONE SCIENTIFIC

Wed, 10 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260610/26626131.html